SK bioscience Co.,Ltd. (KRX:302440)
South Korea flag South Korea · Delayed Price · Currency is KRW
46,950
+150 (0.32%)
At close: Oct 1, 2025

SK bioscience Company Description

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally.

Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.

The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States.

SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. SK bioscience Co.,Ltd. is a subsidiary of SK Chemicals Co.,Ltd.

SK bioscience Co.,Ltd.
CountrySouth Korea
Founded2018
IndustryBiotechnology
SectorHealthcare
Employees917
CEOJae-Yong Ahn

Contact Details

Address:
310, Pangyo-ro
Seongnam-si, 13494
South Korea
Phone82 2 2008 2200
Websiteskbioscience.co.kr

Stock Details

Ticker Symbol302440
ExchangeKorea Stock Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyKRW
ISIN NumberKR7302440003
SIC Code2836

Key Executives

NamePosition
Jae-Yong AhnChief Executive Officer, President and Director
Dr. Sally ChoeHead of Global Clinical Development and Regulatory Affairs